Vita Life Sciences Ltd
Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company offers various minerals, herbs, and superfoods. It markets its products through pharmacies and health food channels under the Herbs of Gold, VitaHealth, and VitaScience brands… Read more
Vita Life Sciences Ltd (VLS) - Net Assets
Latest net assets as of June 2025: AU$52.62 Million AUD
Based on the latest financial reports, Vita Life Sciences Ltd (VLS) has net assets worth AU$52.62 Million AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$74.64 Million) and total liabilities (AU$22.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$52.62 Million |
| % of Total Assets | 70.49% |
| Annual Growth Rate | 2.49% |
| 5-Year Change | 113.9% |
| 10-Year Change | 128.55% |
| Growth Volatility | 49.99 |
Vita Life Sciences Ltd - Net Assets Trend (2000–2024)
This chart illustrates how Vita Life Sciences Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vita Life Sciences Ltd (2000–2024)
The table below shows the annual net assets of Vita Life Sciences Ltd from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | AU$52.28 Million | +20.66% |
| 2023-12-31 | AU$43.33 Million | +18.71% |
| 2022-12-31 | AU$36.50 Million | +19.98% |
| 2021-12-31 | AU$30.42 Million | +24.47% |
| 2020-12-31 | AU$24.44 Million | +8.47% |
| 2019-12-31 | AU$22.53 Million | +0.57% |
| 2018-12-31 | AU$22.41 Million | -9.62% |
| 2017-12-31 | AU$24.79 Million | +6.98% |
| 2016-12-31 | AU$23.18 Million | +1.31% |
| 2015-12-31 | AU$22.88 Million | +6.08% |
| 2014-12-31 | AU$21.57 Million | +32.55% |
| 2013-12-31 | AU$16.27 Million | +43.44% |
| 2012-12-31 | AU$11.34 Million | +26.64% |
| 2011-12-31 | AU$8.96 Million | +10.16% |
| 2010-12-31 | AU$8.13 Million | +108.41% |
| 2009-12-31 | AU$3.90 Million | +1.44% |
| 2008-12-31 | AU$3.85 Million | +33.54% |
| 2007-12-31 | AU$2.88 Million | -13.97% |
| 2006-12-31 | AU$3.35 Million | +124.29% |
| 2005-12-31 | AU$-13.78 Million | -35.19% |
| 2004-12-31 | AU$-10.20 Million | -9.31% |
| 2003-12-31 | AU$-9.33 Million | -169.31% |
| 2002-12-31 | AU$13.46 Million | -66.51% |
| 2001-12-31 | AU$40.18 Million | +38.83% |
| 2000-12-31 | AU$28.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vita Life Sciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 71.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | AU$846.00K | 1.62% |
| Common Stock | AU$45.03 Million | 86.01% |
| Other Comprehensive Income | AU$6.48 Million | 12.38% |
| Total Equity | AU$52.35 Million | 100.00% |
Vita Life Sciences Ltd Competitors by Market Cap
The table below lists competitors of Vita Life Sciences Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Union Auction Public Company Limited
BK:AUCT
|
$31.17 Million |
|
Da Ming International Holdings Limited
F:DM7
|
$31.19 Million |
|
Fino Payments Bank Limited
NSE:FINOPB
|
$31.20 Million |
|
Playside Studios Ltd
AU:PLY
|
$31.21 Million |
|
IMMOBIL.DASSAULT INH.
F:6KP
|
$31.16 Million |
|
FIBI Holdings Ltd
TA:FIBIH
|
$31.16 Million |
|
High Co.
LSE:0O9Y
|
$31.13 Million |
|
Wittchen SA
WAR:WTN
|
$31.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vita Life Sciences Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 43,397,000 to 52,354,000, a change of 8,957,000 (20.6%).
- Net income of 8,784,000 contributed positively to equity growth.
- Dividend payments of 5,169,000 reduced retained earnings.
- Share repurchases of 1,393,000 reduced equity.
- New share issuances of 3,856,000 increased equity.
- Other comprehensive income increased equity by 2,880,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$8.78 Million | +16.78% |
| Dividends Paid | AU$5.17 Million | -9.87% |
| Share Repurchases | AU$1.39 Million | -2.66% |
| Share Issuances | AU$3.86 Million | +7.37% |
| Other Comprehensive Income | AU$2.88 Million | +5.5% |
| Other Changes | AU$-1.00K | -0.0% |
| Total Change | AU$- | 20.64% |
Book Value vs Market Value Analysis
This analysis compares Vita Life Sciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.63x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 27.40x to 2.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | AU$0.09 | AU$2.50 | x |
| 2008-12-31 | AU$0.07 | AU$2.50 | x |
| 2009-12-31 | AU$0.07 | AU$2.50 | x |
| 2010-12-31 | AU$0.14 | AU$2.50 | x |
| 2011-12-31 | AU$0.15 | AU$2.50 | x |
| 2012-12-31 | AU$0.20 | AU$2.50 | x |
| 2013-12-31 | AU$0.29 | AU$2.50 | x |
| 2014-12-31 | AU$0.38 | AU$2.50 | x |
| 2015-12-31 | AU$0.40 | AU$2.50 | x |
| 2016-12-31 | AU$0.41 | AU$2.50 | x |
| 2017-12-31 | AU$0.45 | AU$2.50 | x |
| 2018-12-31 | AU$0.41 | AU$2.50 | x |
| 2019-12-31 | AU$0.41 | AU$2.50 | x |
| 2020-12-31 | AU$0.47 | AU$2.50 | x |
| 2021-12-31 | AU$0.58 | AU$2.50 | x |
| 2022-12-31 | AU$0.68 | AU$2.50 | x |
| 2023-12-31 | AU$0.79 | AU$2.50 | x |
| 2024-12-31 | AU$0.95 | AU$2.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vita Life Sciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.78%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.05%
- • Asset Turnover: 1.11x
- • Equity Multiplier: 1.37x
- Recent ROE (16.78%) is below the historical average (32.40%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 18.13% | 13.87% | 0.77x | 1.69x | AU$2.35 Million |
| 2001 | 0.42% | 0.43% | 0.59x | 1.64x | AU$-3.85 Million |
| 2006 | 335.51% | 88.08% | 0.88x | 4.35x | AU$9.51 Million |
| 2007 | -10.55% | -2.13% | 1.76x | 2.80x | AU$-493.67K |
| 2008 | 10.97% | 2.46% | 1.66x | 2.68x | AU$31.19K |
| 2009 | -9.62% | -1.93% | 1.93x | 2.58x | AU$-669.30K |
| 2010 | 58.28% | 22.09% | 1.39x | 1.90x | AU$3.69 Million |
| 2011 | 14.28% | 5.00% | 1.82x | 1.57x | AU$363.40K |
| 2012 | 21.03% | 7.84% | 1.80x | 1.49x | AU$1.24 Million |
| 2013 | 29.35% | 13.41% | 1.61x | 1.36x | AU$3.13 Million |
| 2014 | 33.91% | 19.90% | 1.21x | 1.41x | AU$5.13 Million |
| 2015 | 19.24% | 11.38% | 1.19x | 1.42x | AU$2.11 Million |
| 2016 | 14.45% | 8.83% | 1.17x | 1.40x | AU$1.03 Million |
| 2017 | 11.56% | 7.59% | 1.15x | 1.33x | AU$387.20K |
| 2018 | 10.90% | 5.93% | 1.15x | 1.60x | AU$201.50K |
| 2019 | 13.88% | 7.39% | 1.16x | 1.62x | AU$876.10K |
| 2020 | 24.65% | 13.11% | 1.19x | 1.58x | AU$3.62 Million |
| 2021 | 26.96% | 14.52% | 1.26x | 1.47x | AU$5.22 Million |
| 2022 | 19.37% | 10.59% | 1.29x | 1.42x | AU$3.43 Million |
| 2023 | 20.92% | 12.24% | 1.24x | 1.38x | AU$4.74 Million |
| 2024 | 16.78% | 11.05% | 1.11x | 1.37x | AU$3.55 Million |
Industry Comparison
This section compares Vita Life Sciences Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $19,254,961
- Average return on equity (ROE) among peers: -149.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vita Life Sciences Ltd (VLS) | AU$52.62 Million | 18.13% | 0.42x | $31.17 Million |
| Aft Pharmaceuticals Ltd (AFP) | $28.23 Million | -47.00% | 1.31x | $53.97 Million |
| Althea Group Holdings Ltd (AGH) | $42.70 Million | -35.24% | 0.26x | $6.03 Million |
| BOD Science Ltd (BOD) | $3.47 Million | -155.95% | 0.53x | $1.38 Million |
| BPH Global Ltd (BP8) | $-1.46 Million | 0.00% | 0.00x | $781.31K |
| Cann Group Ltd (CAN) | $-2.77 Million | 0.00% | 0.00x | $2.39 Million |
| ECS Botanics Holdings Ltd (ECS) | $188.48K | -116.04% | 0.13x | $2.73 Million |
| IDT Australia Ltd (IDT) | $25.01 Million | -24.32% | 0.25x | $8.48 Million |
| Invion Ltd (IVX) | $19.58 Million | -11.45% | 0.02x | $2.48 Million |
| Little Green Pharma Ltd (LGP) | $77.26 Million | -10.55% | 0.12x | $14.26 Million |
| Live Verdure Ltd (LV1) | $362.12K | -1094.69% | 2.55x | $28.27 Million |